PRF Technologies (PRFX) Net Income (2020 - 2024)
PRF Technologies (PRFX) posted quarterly Net Income of $5.3 million for Q2 2024, up 178.28% year-on-year from $1.9 million in Q3 2023, and up 196.64% on a QoQ basis from -$5.5 million in Q1 2024.
PRF Technologies (PRFX) Net Income (2020 - 2024) Analysis & Trends
PRF Technologies (PRFX) has reported Net Income for 5 consecutive years, with $5.3 million the latest figure, recorded in Q2 2024.
- Quarterly Net Income rose 178.28% year-over-year to $5.3 million in Q2 2024, while the trailing twelve-month figure through Dec 2025 was $5.3 million (up 148.7% YoY) and the FY2025 annual result came in at -$5.0 million, up 66.16% from the prior year.
- Net Income grew to $5.3 million in Q2 2024 per PRFX's latest filing, from -$5.5 million in the prior quarter.
- Over the last five years, Net Income for PRFX reached as high as $5.3 million in Q2 2024 and fell as low as -$10.7 million in Q4 2023.
- A 5-year average of -$1.8 million and a median of -$1.7 million in 2021 frame the typical range for Net Income.
- Annual changes were most pronounced in 2022 — Net Income surged 406.35% — and 2024, when it tumbled 338.56%.
- Year by year, Net Income stood at -$4.2 million in 2020, then sank by 65.42% to -$6.9 million in 2021, then decreased by 28.75% to -$8.9 million in 2022, then retreated by 21.01% to -$10.7 million in 2023, then jumped by 149.54% to $5.3 million in 2024.
- According to Business Quant data, Net Income over the past three periods registered $5.3 million, -$5.5 million, and -$10.7 million for Q2 2024, Q1 2024, and Q4 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | PRF Technologies | 745,168.93 | 451,168.93 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 5.32 Mn |
| Mar 31, 2024 | -5.51 Mn |
| Dec 31, 2023 | -10.74 Mn |
| Sep 30, 2023 | 36,000.00 |
| Jun 30, 2023 | -6.80 Mn |
| Mar 31, 2023 | 2.31 Mn |
| Dec 31, 2022 | -8.88 Mn |
| Sep 30, 2022 | 2.11 Mn |
| Jun 30, 2022 | 5.21 Mn |
| Mar 31, 2022 | -1.69 Mn |
| Dec 31, 2021 | -6.89 Mn |
| Sep 30, 2021 | -1.77 Mn |
| Jun 30, 2021 | -1.70 Mn |
| Mar 31, 2021 | -2.04 Mn |
| Dec 31, 2020 | -4.17 Mn |
| Sep 30, 2020 | 1.09 Mn |
| Jun 30, 2020 | 3.26 Mn |
| Mar 31, 2020 | -1.30 Mn |